ACAD - ACADIA Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.21
-0.52 (-2.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close22.73
Open22.58
Bid21.80 x 900
Ask22.50 x 1300
Day's Range22.16 - 23.48
52 Week Range12.77 - 38.00
Volume4,927,045
Avg. Volume2,762,790
Market Cap2.776B
Beta (3Y Monthly)3.95
PE Ratio (TTM)N/A
EPS (TTM)-2.03
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.11
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Acadia Pharmaceuticals: Financial Guidance, Recent Developments
    Market Realist3 days ago

    Acadia Pharmaceuticals: Financial Guidance, Recent Developments

    How Is Acadia Pharmaceuticals Positioned Now? Acadia Pharmaceuticals’ (ACAD) Nuplazid generated revenues of $57.1 million in the second quarter of 2018 compared to $30.5 million in the second quarter of 2017, reflecting an ~87% YoY (year-over-year) growth. After the second quarter of 2018, Acadia Pharmaceuticals lowered its sales revenue guidance for Nuplazid to $210 million–$255 million for fiscal 2018.

  • How Acadia Pharmaceuticals Is Positioned Financially
    Market Realist3 days ago

    How Acadia Pharmaceuticals Is Positioned Financially

    Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will generate revenues of $56.07 million in the third quarter of 2018, representing a ~57.59% YoY (year-over-year) growth. Its net revenues grew ~87% to $57.06 million in the second quarter, from $30.5 million in the second quarter of 2017.

  • Analysts Mostly Positive on Acadia Pharmaceuticals
    Market Realist3 days ago

    Analysts Mostly Positive on Acadia Pharmaceuticals

    Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit4 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • ACCESSWIRE8 days ago

    Today's Research Reports on Trending Tickers: Oragenics and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 12, 2018 / U.S. equities remained bearish on Thursday as worries over rising interest rate and sell-off in technology shares pressure major markets to lower. The Dow ...

  • Here's Why ACADIA Pharmaceuticals Jumped 46% in September
    Motley Fool9 days ago

    Here's Why ACADIA Pharmaceuticals Jumped 46% in September

    The FDA issued a positive statement on the company's drug for Parkinson's disease psychosis, but investors still need to watch one important metric.

  • Investopedia10 days ago

    Biotech Gearing Up for a Pullback?

    There has been no shortage of encouraging news over the past few months across the biotech sector, but the patterns that are appearing on several key charts are suggesting that the story could be in the early stages of shifting. Active traders who are looking for exposure to biotechnology often turn to exchange-traded products such as the SPDR S&P Biotech ETF. As you can see from the chart below, the price has been trading along a well-defined trendline over the past couple of years, but the recent close below the trendline suggests that the ETF is in the early stages of a downtrend.

  • A Look at Portola Pharmaceuticals’ Financial Performance
    Market Realist11 days ago

    A Look at Portola Pharmaceuticals’ Financial Performance

    Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018, which reflected ~6% year-over-year (or YoY) growth. Portola Pharmaceuticals’ net revenues grew from $8.92 million in the first half of 2018 to $10.66 million in the first half of 2017, reflecting ~20% YoY growth.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit12 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
    Market Realist23 days ago

    Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday

    In the second quarter, Acadia Pharmaceuticals reported net revenues of $57.1 million compared to $30.5 million in Q2 2017. Acadia Pharmaceuticals’ revenue growth could boost the share price of the First Trust NYSE Arca Biotechnology Index Fund (FBT). Acadia Pharmaceuticals’ peers in the biopharmaceuticals market include Progenics Pharmaceuticals (PGNX), Sarepta Therapeutics (SRPT), and Amicus Therapeutics (FOLD).

  • Investopedia23 days ago

    3 Biotechs Poised for 10% Gains

    Technical analysis suggests that Acadia Pharmaceuticals Inc. ( ACAD), BeiGene Ltd. ( BGNE) and Intercept Pharmaceuticals Inc. ( ICPT) are three such stocks that could see the significant gains. Acadia shares have skyrocketed higher over the past few weeks and are trading around a technical resistance level at $21.50. Should the stock be able to rise above that level of resistance, the shares could rally by 13% to a price of $24, from its current price of around $21.40.

  • Simply Wall St.23 days ago

    ACADIA Pharmaceuticals Inc (NASDAQ:ACAD): Financial Strength Analysis

    Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) with a market-capitalization of US$2.48b, rarely draw their attention. Despite this, commonly overlooked Read More...

  • Business Wire24 days ago

    ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science

    -Robert Kaper, M.D., named Senior Vice President, Global Head of Medical Affairs

  • Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
    Zacks24 days ago

    Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars

    Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.

  • See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
    Markit24 days ago

    See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.

    ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

  • ACCESSWIRE24 days ago

    Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Array BioPharma

    NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...

  • Why Is Amarin’s Stock Price Soaring?
    Market Realist24 days ago

    Why Is Amarin’s Stock Price Soaring?

    Today, Amarin Corporation stock is trading at $13.77, versus yesterday’s closing price of $12.40, reflecting ~11.05% growth. On September 24, Amarin’s stock price grew 314.7% to reach $12.40, versus $2.99 on September 21.

  • Business Wire25 days ago

    ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018

    ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 9:45 a.m. Eastern Time in New York City. ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

  • TheStreet.com25 days ago

    8 Stocks Poised to Change Direction

    Below is a list of names for those charts we believe are showing technical characteristics of either bullish or bearish reversal patterns that occurred over the past week. Bullish reversals imply institutional accumulation and the potential for higher prices.

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: Geron and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 24, 2018 / U.S. markets were mixed on Friday, with the Dow Jones managing to close at an all-time high despite a plunge in technology and internet stocks. The Dow Jones Industrial Average gained 0.32 percent to close at 26,743.50, while the S&P 500 Index declined 0.04 percent to close at 2,929.67. The Nasdaq Composite Index decreased 0.51 percent to close at 7,986.96.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool28 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these sizzling-hot biotechs keep the momentum going?

  • FDA Confirms Positive Safety Profile of Acadia's Nuplazid
    Zacks28 days ago

    FDA Confirms Positive Safety Profile of Acadia's Nuplazid

    Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.

  • Benzinga29 days ago

    Acadia's FDA Boost Is Just The Beginning, Piper Jaffray Says In Upgrade

    The Food and Drug Administration assigned ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )’s Nuplazid a positive safety profile Thursday, sending shares soaring 27 percent. The run is just getting started, ...

  • GlobeNewswire29 days ago

    FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against ACADIA Pharmaceuticals Inc. (ACAD) & Lead Plaintiff Deadline - September 17, 2018

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc.  (“Acadia” or the “Company”) (ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Acadia securities between April 29, 2016 and July 9, 2018, (the “Class Period”).  Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acad. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.